- DARZALEX® is not chemotherapy. DARZALEX® is a monoclonal antibody that works with your immune system. Monoclonal antibodies work by attaching themselves to multiple myeloma cells in your body and directly killing them, and/or signaling your immune system to destroy them
- DARZALEX® finds and attaches to a protein called CD38, which is present on the surface of cells, including high numbers on myeloma cells
The main goal of the study was to measure the length of time patients live without their multiple myeloma getting worse or their passing away from any cause
- Another goal was to measure response rate, which is the percentage of patients who responded to treatment. Talk to your doctor about how response is measured
The majority of patients responded to the following DARZALEX® combination treatments:
DARZALEX® was studied in combination with Revlimid® and dexamethasone (Rd) vs Rd alone in 569 patients who had received a minimum of 1 prior treatment
- 9 out of 10 patients responded to DARZALEX® + Rd vs 7 out of 10 with Rd alone
DARZALEX® was studied in combination with Velcade® and dexamethasone (Vd) vs Vd alone in 498 patients who had received a minimum of 1 prior treatment
- Almost 8 out of 10 patients responded to DARZALEX® + Vd vs almost 6 out of 10 with Vd alone
- DARZALEX® was studied in combination with Revlimid® and dexamethasone (Rd) vs Rd alone in 569 patients who had received a minimum of 1 prior treatment
- DARZALEX® combination treatments reduced patients’ risk of their disease getting worse or their passing away from any cause by more than 60%
Click here if you are a healthcare professional.
Revlimid® is a registered trademark of Celgene Corporation.
Velcade® is a registered trademark of Millennium Pharmaceuticals, Inc.
When your multiple myeloma relapses again and again,
My Reason toDiscoverWhat’s Possible
DARZALEX® (daratumumab) is a prescription medicine used to treat a type of cancer called multiple myeloma in people who:
- Have received at least 3 prior medicines to treat multiple myeloma, including a proteasome inhibitor (PI) and an immunomodulatory agent, or
- Did not respond to a PI and an immunomodulatory agent
It is not known if DARZALEX® is safe and effective in children.
DARZALEX® is approved based on response. Clinical trials are still ongoing.
How does DARZALEX® work?
DARZALEX® is a monoclonal antibody that works with your immune system. Ask your doctor if
DARZALEX® finds and attaches to a protein called CD38, which is present on the surface of cells, including high numbers on myeloma cells.
Once DARZALEX® attaches to the CD38 protein, it works in many ways, by helping your immune system find and kill myeloma cells and/or by killing the myeloma cells on its own.
* Please note that dates provided are recommendations for infusion visits only. Your doctor is likely to schedule additional follow-up/care visits and may alter the dates for your infusions depending on your availability and office availability.
Please contact the center to confirm hours of operation.
Would you like to clear your old dosing schedule and create a new one?
Want a PDF of this treatment schedule?
Learn what you can expect before treatment with DARZALEX®.
Learn from patients on DARZALEX® and their caregivers about their experiences.
Learn about some useful tips to help you prepare for your infusion and feel comfortable during your appointments.
Janssen CarePath provides ongoing support, education, and resources during your treatment with DARZALEX®.